Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    tetanus and ibd
Previous Study | Return to List | Next Study

Cross Sectional Study of Vaccine Antibody Response in Inflammatory Bowel Disease Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02434133
Recruitment Status : Completed
First Posted : May 5, 2015
Last Update Posted : November 27, 2018
Sponsor:
Information provided by (Responsible Party):
University of Wisconsin, Madison

Brief Summary:
The investigators proposed study is the first of its kind. The investigators will measure measles, mumps, rubella, tetanus, diphtheria and pertussis antibodies in patients on the current IBD treatment modalities and compare the vaccine antibody concentrations and correlate them with time since immunization.

Condition or disease Intervention/treatment
Inflammatory Bowel Disease (IBD) Procedure: Blood Draw/Data Collection

Detailed Description:

Tetanus and diphtheria have become rare diseases because of widespread immunization that began during World War II. The percentage of people who got pertussis (whooping cough) also went down after vaccination, but large outbreaks have occurred over the past decade. Measles, mumps, rubella (German measles) and varicella (chicken pox) are illnesses that resolve quickly, but which can cause other diseases to take hold or get worse. Routine vaccination can prevent infection and has been and recommended for use in the United States beginning in the 1960s and 1970s; and in 1995 for varicella. Today measles, mumps, and rubella are especially uncommon in the U.S. thanks to vaccination programs; and the percentage of people with varicella is going down. Despite widespread vaccination efforts, there have been recent outbreaks of measles and mumps in the U.S., in part because these diseases are still common in other parts of the world.

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract which includes Crohn's disease (CD) and ulcerative colitis (UC). Treatment options for IBD consist of immunosuppressive therapy, meaning that the drugs weaken the immune system, such as systemic corticosteroids, immunomodulators (thiopurines and methotrexate) and/or biologics, such as tumor necrosis factor alpha (TNF) agents or an integrin inhibitor (vedolizumab). Patients with IBD can achieve clinical remission and decrease the risk of complications with treatment; however, treatment can also increase the risk for infections because they weaken the immune system. Some of these infections are preventable with routine vaccination.

You are invited to take part in this research project to determine if people with IBD on different types of therapy have a lower amount of antibodies than healthy individuals. Antibodies are proteins used by the immune system to attack viruses like tetanus and measles. Antibodies can be introduced into the body through vaccines. The fewer antibodies there are, the harder it is for the antibodies to attack a virus, meaning that the person could get sick with a virus. This research project will help us figure out whether people with IBD have fewer antibodies than people without IBD. The investigators will also look at whether the type of treatment people take for IBD affects the amount of antibodies. T

This will tell us who is more likely to get sick from viruses, and why. The investigators will recruit 90 IBD patients under treatment for their IBD as well as 20 healthy controls for a total of 110 patients at the University of Wisconsin Hospital & Clinics.

Layout table for study information
Study Type : Observational
Actual Enrollment : 110 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Cross Sectional Study of Vaccine Antibody Response in Inflammatory Bowel Disease Patients
Study Start Date : April 2015
Actual Primary Completion Date : April 2016
Actual Study Completion Date : December 2017

Group/Cohort Intervention/treatment
Case (Group A)
Group A (Immunomodulator) currently taking azathioprine or 6- mercaptopurine (Blood Draw)
Procedure: Blood Draw/Data Collection
Participation will involve an extra 8ml tube of blood and a review of their medical records for medications and immunization history.

Case (Group B)

Group B (Biologic group) currently taking anti-TNF therapy (infliximab, golimumab, adalimumab, or certolizumab).

(Blood Draw)

Procedure: Blood Draw/Data Collection
Participation will involve an extra 8ml tube of blood and a review of their medical records for medications and immunization history.

Case (Group C)
Group C (Combination therapy) currently taking anti-TNF therapy and an immunomodulator (including methotrexate) (Blood Draw)
Procedure: Blood Draw/Data Collection
Participation will involve an extra 8ml tube of blood and a review of their medical records for medications and immunization history.

Control

Individuals will be obtained from patients without an IBD diagnosis coming to Digestive Health Center for endoscopic procedures or clinic visits.

(Blood Draw)

Procedure: Blood Draw/Data Collection
Participation will involve an extra 8ml tube of blood and a review of their medical records for medications and immunization history.




Primary Outcome Measures :
  1. To compare antibody concentrations and seroprotection rates [ Time Frame: 12 month study ]
    To compare tetanus, diphtheria, and pertussis antibody concentrations and seroprotection rates in patients with IBD treated with combination therapy to healthy individuals.

  2. To compare antibody concentrations and seroprotection rates [ Time Frame: 12 month study ]
    To compare measles, mumps, and rubella antibody concentrations and seroprotection rates in patients with IBD treated with combination therapy to healthy individuals.


Biospecimen Retention:   Samples With DNA
Blood sample to measure antibody concentration


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
The subject population will consist of individuals with inflammatory bowel disease and healthy controls.
Criteria

Inclusion Criteria

  • A history of chronic (greater than 3 month) ulcerative colitis or Crohn's disease diagnosed and documented by the standard clinical, radiographic, endoscopic and histopathologic criteria.
  • Undergoing blood work the day of the study visit for routine blood monitoring due to medication.
  • Has a documented tetanus-diphtheria (Td) or tetanus-diphtheria-acellular pertussis (Tdap) in the Wisconsin Immunization Registry (WIR) at least 4 weeks prior to entering study.
  • Has a document measles, mumps and rubella (MMR) in the Wisconsin Immunization Registry (WIR) at least 4 weeks prior to entering study. This will need to be met by 50% of patient in group A-C.
  • Is currently taking one of the following medication regimens for at least 3 months.
  • Group A (Immunomodulator) currently taking azathioprine or 6- mercaptopurine
  • Group B (Biologic group) currently taking anti-TNF therapy (infliximab, golimumab, adalimumab, or certolizumab).
  • Group C (Combination therapy) currently taking anti-TNF therapy and an immunomodulator (including methotrexate)
  • The patient must understand and voluntarily sign the informed consent document.

Exclusion Criteria

  • Unconfirmed Td or Tdap vaccination status
  • Patients in whom venipuncture are not feasible due to poor tolerability or lack of easy access.

CONTROLS Inclusion Criteria

  • Has a documented tetanus-diphtheria (Td) or tetanus-diphtheria-acellular pertussis (Tdap) in the Wisconsin Immunization Registry (WIR) at least 4 weeks prior to entering study.
  • Has a document measles, mumps and rubella (MMR) at least two injections in the Wisconsin Immunization Registry (WIR) at least 4 weeks prior to entering study.

CONTROLS Exclusion Criteria

  • Currently on immunosuppressive therapy
  • Has a chronic health condition that may have an impact on vaccine antibody concentrations as deemed by the investigators, including chronic liver disease, celiac disease, history of solid organ or bone marrow transplantation.
  • Older than age 65 years
  • Unconfirmed MMR vaccination status
  • Patients in whom venipuncture are not feasible due to poor tolerability or lack of easy access.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02434133


Locations
Layout table for location information
United States, Wisconsin
University of Wisconsin Hospital & Clinics
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
University of Wisconsin, Madison

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Wisconsin, Madison
ClinicalTrials.gov Identifier: NCT02434133    
Other Study ID Numbers: 2015-0340
Tetanus/MMR ( Other Identifier: UW-Madison Study Staff )
First Posted: May 5, 2015    Key Record Dates
Last Update Posted: November 27, 2018
Last Verified: November 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Intestinal Diseases
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Gastroenteritis
Antibodies
Immunologic Factors
Physiological Effects of Drugs